Skip to Main Content

Alexion Pharmaceuticals, until recently seen as one of biotech’s biggest success stories, is eliminating roughly 600 jobs and moving its headquarters to Boston amid federal investigations and pressure to cut costs.

The company made its name on Soliris, a treatment for rare diseases that — at a cost of about $700,000 a year — is also the world’s most expensive drug. But after a series of pipeline disappointments and an ill-advised $8.4 billion acquisition, Alexion is facing an uncertain future.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.